[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ccus-clonal-cytopenia-of-undetermined-significance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ccus-clonal-cytopenia-of-undetermined-significance":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,74,97,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100534586","phase-2-enasidenib-for-patients-with-clonal-cytopenia-of-undetermined-significance-and-mutations-in-idh2a-decentralized-trial-100534586",false,"NCT06240754","Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial","A Pilot Study of Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2: A Decentralized Trial","Inclusion Criteria:\n\n* Unexplained cytopenia for at least 6 months. Cytopenia is defined as the presence of ≥1 blood count indexes below the following thresholds:\n\n  * Hgb \\\u003C10 g\u002FdL\n  * ANC \\\u003C1.8 × 109\u002FL\n  * Platelets \\\u003C100 × 109\u002FL\n* IDH2 gene mutation (R140 or R172), performed locally, at a frequency ≥ 2%.\n* At least 18 years of age.\n* ECOG performance status 0-2\n* Adequate organ function as defined below:\n\n  * AST(SGOT)\u002FALT(SGPT) ≤ 3.0 x IULN\n  * Serum total bilirubin \\\u003C 1.5 x IULN (un upper limit of bilirubin 5 mg\u002FdL is acceptable if it can be attributed to Gilbert's syndrome or erythropoiesis)\n  * Creatinine clearance \\> 50 mL\u002Fmin by Cockcroft-Gault glomerular filtration rate estimation or serum creatinine ≤ 2 x IULN\n* The effects of enasidenib on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 24 months after the last dose of enasidenib. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and for 4 months after the last dose of enasidenib.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria:\n\n* Indication of hematologic disease by bone marrow biopsy within 6 months of study entry.\n\n  * Evidence of disease progression from time of bone marrow biopsy to enrollment based on investigator review of symptoms and complete blood counts\n* Active malignancy (defined as \\> 1 cm disease on most recent CT scan in the past 6 months).\n* Currently receiving therapy for solid tumor malignancy or received within the last 6 months.\n* Currently receiving any other investigational agents.\n* Known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to enasidenib or other agents used in the study.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative pregnancy test within 72 hours of study entry.\n* Positive direct Coombs test.","ALL","18 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.",[26,27],"Clonal Cytopenia of Undetermined Significance","CCUS Clonal Cytopenia of Undetermined Significance",[26,29,30,31],"CCUS","IDH2","Enasidenib","RECRUITING","2026-05-22",{"date":35,"type":36},"2026-05-27","ACTUAL",{"date":38,"type":36},"2024-10-10",{"date":40,"type":20},"2029-02-28",{"name":42,"class":43},"Washington University School of Medicine","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":44},"100617010","chapter-clonal-haematopoiesis-assessment-prevention-treatment-and-research-100617010","NCT07313059","CHAPTER: Clonal Haematopoiesis Assessment: Prevention, Treatment and Research","Prospective Clinical Evaluation of Incidence, Outcomes and Individuals Experiences Following Diagnosis of Clonal Haematopoiesis in a Dedicated Research Clinic","CHAPTER","Inclusion Criteria:\n\n1. Aged 55 years and above\n2. Confirmed CH or possible CH, with possible CH defined by:\n\n   a. Persistent, non-severe cytopenia, characterised by one or more of the following, present on at least 2 occasions, at least 4 months apart (WHO criteria): i. Absolute neutrophil count (ANC) \\\u003C 1.8 x 109\u002FL ii. Haemoglobin (Hb) \\\u003C 120 g\u002FL in females, \\\u003C 130 g\u002FL in males iii. Platelet count \\\u003C 150 x 109\u002FL\n3. Provision of written informed consent prior to any study-related assessments or procedures being carried out.\n\nExclusion Criteria:\n\n1. Severe cytopenia as defined by one or more of the following:\n\n   1. ANC \\\u003C 0.5 x109\u002FL\n   2. Hb \\\u003C 80 g\u002FL\n   3. Platelet count \\\u003C 50 x 109\u002FL\n2. Multilineage cytopenias:\n\n   a. Marked trilineage cytopenia with all the following present: i. ANC \\\u003C 1.0 x 109\u002FL AND ii. Hb \\\u003C 110 g\u002FL AND iii. Platelet count \\\u003C 100 x 109\u002FL\n\n   b. Marked bilineage cytopenia, with two or more of the following present: i. ANC \\\u003C 1.0 x 109\u002FL ii. Hb \\\u003C 110 g\u002FL iii. Platelet count \\\u003C 100 x 109\u002FL\n\n   Note: People with possible CH, with the above characteristics will be excluded from referral to the CH clinic and will instead have urgent investigation as an inpatient or in the haematology clinic. However, if no definite cause for cytopenia is identified, including CH, then individuals may be referred for CH screening at the CH clinic the discretion of the study PI","55 Years",{"count":55,"type":20},100,"5 Years","OBSERVATIONAL","People identified to have CH or thought to have possible CH due to unexplained low blood cell counts, including low red blood cells, white blood cells, or platelets will be asked to take part in the study.\n\nIndividuals who are confirmed to have CH and provide informed consent to participate in the study will have monitoring of their CH, assessment of the risk of heart diseases, blood cancers and personalised support. The researchers will also measure people's understanding of CH and how they feel after learning about CH.\n\nResearchers will then record the relevant information from people with CH in a central database over time to track long-term health outcomes.\n\nThe information collected from the study will help create a blueprint for doctors to provide care for people with CH in the future, and guide further research into CH in Australia.\n\nParticipants will be asked to donate blood samples for the study for research purposes including CH monitoring and testing and also provide health information for the central database.",[60,27,61],"Clonal Hematopoiesis","Hematologic Disease and Disorders",[60,63,29],"CH","2026-05-11",{"date":66,"type":36},"2026-05-13",{"date":68,"type":36},"2026-03-20",{"date":70,"type":20},"2033-11",{"name":72,"class":73},"Clinical Hub for Interventional Research (CHOIR)","OTHER_GOV",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100636107","dresden-mds-registry-with-an-accompanying-biomaterial-collection-100636107","NCT07561385","Dresden MDS Registry With an Accompanying Biomaterial Collection","Inclusion Criteria:\n\n* Diagnosis of myelodysplastic syndrome (MDS), MDS\u002FMPN overlap syndrome or evidence of myelodysplastic precursor syndrome, defined as clonal haematopoiesis without cytopenia (clonal haematopoiesis of indeterminate potential, CHIP) or clonal haematopoiesis with cytopenia (clonal cytopenia of undetermined significance, CCUS) in accordance with current WHO criteria\n* Age ≥18 years\n* Submission of a signed consent form for participation in the MDS Registry\n\nExclusion Criteria:\n\n* No exclusion criteria have been established with regard to the registry's primary objective. In particular, patients with comorbidities and those receiving non-curative treatment may be explicitly included in order to provide a realistic picture of actual care practices\n* Inclusion in the registry is excluded in cases where a written consent form is not available or where patients are unable to understand the nature and implications of participating in this registry",{"count":81,"type":20},500,"A registry for the study of the epidemiology, clinical course, and progression of myelodysplastic neoplasms (MDS), myelodysplastic\u002Fmyeloproliferative neoplasms (MDS\u002FMPN overlap syndromes), and their precursor syndromes (CHIP, CCUS)",[84,85,86,27],"MDS (Myelodysplastic Syndrome)","MDS\u002FMyeloproliferative Neoplasm (MPN) Overlap Syndrome","CHIP","NOT_YET_RECRUITING","2026-04-24",{"date":90,"type":36},"2026-05-01",{"date":92,"type":20},"2026-06",{"date":94,"type":20},"2036-06",{"name":96,"class":43},"Technische Universität Dresden",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":44},"100576699","phase-2-luspatercept-for-clonal-cytopenias-of-uncertain-significance-100576699","NCT06788691","Luspatercept for Clonal Cytopenias of Uncertain Significance","Efficacy of Luspatercept In Clonal Cytopenias of Uncertain Significance","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age.\n* Documentation of a CCUS diagnosis.\n\n  * Clonal cytopenia of undetermined significance (CCUS) is defined as clonal hematopoiesis of indeterminate potential (CHIP) detected in the presence of one or more persistent cytopenias that are otherwise unexplained by hematologic or non-hematologic conditions and that do not meet diagnostic criteria for defined myeloid neoplasms. Cytopenia definitions for diagnosis of CCUS include Hb \\\u003C13 g\u002FdL in males and \\\u003C12 g\u002FdL in females for anemia, absolute neutrophil count \\\u003C1.8 ×109\u002FL for leukopenia, and platelets \\\u003C150 × 109\u002FL for thrombocytopenia.\n  * Patients should harbor somatic mutations of myeloid malignancy-associated genes detected in the blood or bone marrow at a variant allele fraction (VAF) of ≥ 2% (≥4% for X-linked gene mutations in males\n* Clinically significant cytopenias demonstrated in two separate lab draws and defined as cytopenia in any one of the following:\n\n  * Anemia: Transfusion dependent (LTD or HTD for Hb \\\u003C 9 g\u002FdL based on IWG 2018 criteria). Exception for higher threshold up to 10g\u002FdL for documented moderate or severe angina pectoris, cardiac or pulmonary insufficiency, or ischemic neurologic diseases (per IWG 2018 consensus recommendation).\n  * Anemia NTD: symptomatic NTD CCUS with Hb \\\u003C10 g\u002Fdl, symptomatic defined as moderate or worse on ≥ 1 Patient Global Impression of Severity (PGI-S) item (fatigue, shortness of breath, weakness, or dizziness)\n  * Thrombocytopenia: platelet count less than 30,000 \u002FmicroL or \\\u003C 50,000\u002FmicroL with documented bleeding events or high risk for bleeding, for example on blood thinners or drugs that inhibit platelet function for other comorbidities.\n  * Neutropenia: Neutropenia below 750\u002Fmicrol are included in the study. For subjects with neutropenia between 750-1000\u002Fmicrol, subjects should have neutropenia AND a history of serious infection(s).\n* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2\n* Adequate organ function as defined by:\n\n  * Direct bilirubin \\\u003C 3 x ULN. Indirect hyperbilirubinemia from hemolysis or Gilberts disease are not considered as impaired.\n  * Estimated Creatinine clearance or GFR \\>30 ml\u002Fmin by institutional standards (for example MDRD or Cockcroft Gault or measured by 24 hour urine clearance).\n  * ALT and AST \\\u003C 3 x ULN\n* Females of childbearing potential (FCBP), defined as a sexually mature woman who: 1) has achieved menarche at some point, 2) not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy or amenorrhea due to other medical reasons does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months), must:\n\n  * Have two negative pregnancy tests (serum or urine) as verified by the investigator prior to starting study therapy (unless the screening pregnancy test was done within 72 hours of W1D1). She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment.\n  * Either commit to true abstinence1 from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, highly effective contraception2 without interruption, 5 weeks prior to starting investigational product, during the study therapy (including dose interruptions), and for 12 weeks after discontinuation of study therapy.\n\nMale subjects must:\n\n\\- Practice true abstinence1(which must be reviewed prior to each IP administration or on a monthly basis \\[e.g., in the event of dose delays\\]) or agree to use a condom (latex or non-latex, but not made out of natural \\[animal\\] membrane) during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 12 weeks following investigational product discontinuation, even if he has undergone a successful vasectomy.\n\nContraception\n\n* True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. \\[Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\\].\n* Highly effective contraception is defined in this protocol as the following (information will also appear in the ICF): Hormonal contraception (for example, birth control pills, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation (tying your tubes); or a partner with a successful vasectomy.\n\nExclusion Criteria:\n\n* Concurrent malignancy requiring active concurrent systemic chemotherapy. Hormonal therapy for malignancy and targeted radiation is allowed. If patients after enrollment, have a clinical need for chemotherapy after achieving response on treatment, subjects deriving clinical benefit can be continued on study after discussion with study PI.\n* Diagnosis of MDS, AML, MPN or any other myeloid malignancy in the patient's lifetime\n* Active uncontrolled infection that in the investigators opinion will affect study procedures and\u002For results\n* Active uncontrolled hypertension not responding to blood pressure lowering medications which in the investigator's opinion will be harmful for the patient.\n* Use of ESA or growth factors within four weeks prior to the start of the study\n* Known risk factors for thromboembolism (splenectomy, concomitant use of hormone replacement therapy or recent uncontrolled pulmonary embolism or DVT in the last 6 months). Subjects adequately controlled on anticoagulation are permitted.\n* Pregnant or nursing women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using basic methods of contraception during dosing of study treatment and for up to 130 days after last dose of study drug. Basic contraception methods are defined in Section 4.4.\n\n  * Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks prior to first dose of study drug. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the Informed Consent Form (ICF).",{"count":105,"type":20},50,[23],"The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include:\n\n* How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)?\n* How long these improvements last before the condition worsens or changes.\n* The percentage of participants showing improvements at 12, 24, and 48 weeks.\n* How long it takes for the condition to progress to more severe diseases like myeloid disorders.\n* How long red blood cell responses last and how quickly these responses are seen.\n* The average change in hemoglobin levels over 24 weeks.\n* How many patients need blood transfusions during the study and how soon transfusions are required.\n* Changes in participants' well-being and energy levels based on a standardized questionnaire.\n* Monitoring for any side effects, including progression to MDS or leukemia, heart-related issues, or sudden increases in hemoglobin.\n\nParticipants will:\n\n* Receive luspatercept as an injection every three weeks.\n* Visit the clinic every three weeks for treatment and monitoring.",[27,109,110,111,112],"Anemia","Leukopenia","Thrombocytopenia","Neutropenia",{"date":114,"type":36},"2026-03-24",{"date":116,"type":36},"2025-03-25",{"date":118,"type":20},"2028-02",{"name":120,"class":43},"Weill Medical College of Cornell University",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},"100626438","phase-2-modulation-of-stem-cell-differentiation-in-individuals-with-high-risk-clonal-haematopoiesis-100626438","NCT07435636","Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal Haematopoiesis","A Multi-centre, Double-blind, Placebo-controlled Randomised Phase II Trial to Evaluate the Effect of Low Dose Decitabine and Tetrahydrouridine in Individuals With High-risk Clonal Haematopoiesis","MOSAIC","Inclusion Criteria:\n\n1. Age ≥ 60 and ≤ 85 years old\n2. Clonal Cytopenia of Uncertain Significance (CCUS), defined by all of the following:\n\n   a. Persistent cytopenia, present on at least two occasions, at least four months apart, with no other cause identified: i. Hemoglobin (Hb) \\\u003C 120 g\u002FL in people born female, and \\\u003C 130 g\u002FL in people born male ii. Platelet count \\\u003C 150 x 109\u002FL iii. Absolute Neutrophil Count (ANC) \\\u003C 1.8 x109\u002FL b. Clonal hematopoiesis (CH) driver mutation confirmed by custom gene panel mutation analysis c. absence of features diagnostic for defined myeloid neoplasm (MN) on bone marrow examination\n3. CH driver mutation variant allele fraction (VAF) of ≥ 10%\n4. For participants living with HIV:\n\n   1. Receiving and adherent to suppressive antiretroviral therapy for at least 12 months\n   2. CD4+T cell count ≥ 0.35 x 109\u002FL\n   3. HIV viral load \\\u003C 50 copies\u002FmL\n\n6\\. Performance status by Eastern Cooperative Oncology Group (ECOG) Criteria of 0 or 1 7. For participants who are of childbearing potential, or whose partners are of childbearing potential:\n\n1. Agreement to use at least two highly effective (per Clinical Trial Facilitation Group) contraceptive methods throughout the course of the trial, and for 6 months following the last dose of trial drug\n2. Refrain from donating eggs or sperm during the same period\n3. Confirmation of a negative serum pregnancy test at screening and at the beginning of each treatment cycle visit (for female participants of childbearing potential) 8. Provision of signed written informed consent document prior to any trial-related assessments or procedures being carried out\n\nExclusion Criteria:\n\n1. ANC \\\u003C 0.5 x109\u002FL\n2. Serum AST (Aspartate transaminase) or ALT (Alanine aminotransaminase) \\> 3 times of upper limit of normal\n3. Calculated or measured creatinine clearance ≤ 50 mL\u002Fmin\n4. Significant active cardiac disease within the previous 6 months, including:\n\n   1. New York Heart Association (NYHA) class III or IV congestive heart failure\n   2. Unstable angina or angina requiring surgical or medical intervention\n   3. Myocardial infarction\n   4. New or unstable cardiac arrhythmia. Stable or controlled arrhythmias are permitted\n5. Active systemic infections:\n\n   1. Infection with ongoing signs\u002Fsymptoms related to the infection without improvement despite appropriate anti-infectives\n   2. Active Hepatitis B infection (HBV) (defined as HBsAg positive, or HBcAb positive and measurable HBV DNA; participants who are HBcAb positive must have HBV DNA assayed during screening)\n   3. Active Hepatitis C Virus (HCV) will be ineligible if there is clinical hepatic dysfunction or other systemic manifestations of HCV disease, or if the hepatic eligibility parameters above are not met. Consideration should be given to curative HCV therapy prior to enrolment in consultation with HCV clinician\n6. Any history of hematological or solid malignancy in previous the 5 years unless the participant has been free of disease for ≥ 36 months. However, participants with the following history\u002Fconcurrent conditions are not excluded:\n\n   1. Basal or squamous cell carcinoma of the skin\n   2. Carcinoma in situ of the cervix\n   3. Carcinoma in situ of the breast\n   4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis \\[TNM\\] clinical staging system)\n7. Known hypersensitivity to trial drugs or their constituents\n8. Currently enrolled in the treatment phase of an interventional investigational trial.\n9. Pregnant or breast-feeding individuals\n10. Any condition not already outlined above which, in the opinion of the Principal Investigator, would place the participant at risk if they participated or would jeopardize adherence, follow up, or confound the ability to interpret trial data","60 Years","85 Years",{"count":132,"type":20},80,[23],"Clonal hematopoiesis (CH) is characterized by the overproduction of blood cells derived from a single hematopoietic stem and progenitor cell (HSPC) harboring certain somatic mutations. It is linked to serious outcomes, including cardiovascular disease, myeloid neoplasm (MN), and increased mortality.\n\nClonal Cytopenia of Uncertain Significance (CCUS) is a CH subtype characterized by associated persistent cytopenia. It affects approximately 10 % of people over 70 and is the most advanced precursor state with the highest risk of progressing to MN. There is an unmet need to determine whether modifying CH can prevent adverse outcomes. Current blood cancer therapies are too toxic for precursor conditions like CH.\n\nMOSAIC is a randomized double-blind placebo-controlled trial that will test a novel low-dose oral epigenetic therapy-decitabine with tetrahydrouridine (Dec+THU) in CCUS. It has shown targeted, non-cytotoxic reversal of common CH mutations in preclinical and early-phase studies.\n\nThe goal is to develop a safe and effective therapy in CCUS that restores normal blood cell production and prevents progression.",[136,27,60],"Clonal Cytopenia of Uncertain Significance",[127,63,138,29,139,140,141,136],"Modulation of stem cell differentiation","persistent cytopenia","clonal hematopoiesis","clonal haematopoiesis","2026-02-23",{"date":144,"type":36},"2026-02-27",{"date":146,"type":20},"2026-04-13",{"date":148,"type":20},"2030-10",{"name":72,"class":73},3]